GHRS GH Research
- 11.680
- +0.490+4.38%
- 11.290
- -0.390-3.34%
GH Research News
Analysts Offer Insights on Healthcare Companies: Veru (VERU) and GH Research (GHRS)
Express News | GH Research PLC - Phase 2a Clinical Trial of GH001 in Postpartum Depression on Track for Expected Completion in Q3 2024
Express News | GH Research - Cash, Cash Equivalents, Other Financial Assets and Marketable Securities of $214.0 Mln Expected to Provide Cash Runway Into 2026
Express News | GH Research PLC Q1 EPS USD -0.15
GH Research: Cash Runway Into 2026 >GHRS
GH Research: Cash Runway Into 2026 >GHRS
GH Research 1Q Loss/Shr 15c >GHRS
GH Research 1Q Loss/Shr 15c >GHRS
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized AnxietyPsilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits f
Express News | HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target
Buy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advances
Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success wi
GH Research Price Target Cut to $39.00/Share From $50.00 by JMP Securities
GH Research Price Target Cut to $39.00/Share From $50.00 by JMP Securities
GH Research Is Maintained at Market Outperform by JMP Securities
GH Research Is Maintained at Market Outperform by JMP Securities
Express News | JMP Securities Maintains Market Outperform on GH Research, Lowers Price Target to $39
Oregon House Passes Bill to End Hard Drug Decriminalization
There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.
Buy Rating Justified by GH Research's Promising Clinical Trials and Strong Financial Health
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
Nasdaq-listed, GH Research (NASDAQ:GHRS) is a clinical-stage biopharma business developing novel 5-MeO-DMT therapies as transformative treatment of psychiatric and neurological disorders.Its reported
GH Research: Q4 Earnings Insights
GH Research (NASDAQ:GHRS) reported its Q4 earnings results on Thursday, February 29, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsGH Research missed estimated ear
Analysis
Price Target
No Data
